{"id":"https://openalex.org/W4283333293","doi":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","title":"P1087: FAVEZELIMAB (ANTI\u2013LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI\u2013PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY","display_name":"P1087: FAVEZELIMAB (ANTI\u2013LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI\u2013PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4283333293","doi":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3"},"language":"en","primary_location":{"id":"doi:10.1097/01.hs9.0000847216.85071.f3","doi":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030788778","display_name":"Alex Francisco Herrera","orcid":"https://orcid.org/0000-0002-9665-7415","observed_orcids":["https://orcid.org/0000-0002-9665-7415"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]},{"id":"https://openalex.org/I4210110459","display_name":"City of Hope","ror":"https://ror.org/01z1vct10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"A. F. Herrera","raw_affiliation_strings":["City of Hope, Duarte, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope, Duarte, United States of America","institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019626882","display_name":"David Lavie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799899409","display_name":"Hadassah Medical Center","ror":"https://ror.org/01cqmqj90","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2799899409"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"D. Lavie","raw_affiliation_strings":["Hadassah Medical Center, Jerusalem, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hadassah Medical Center, Jerusalem, Israel","institution_ids":["https://openalex.org/I2799899409"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039588431","display_name":"Nathalie A. Johnson","orcid":"https://orcid.org/0000-0002-3211-9722","observed_orcids":["https://orcid.org/0000-0002-3211-9722"]},"institutions":[{"id":"https://openalex.org/I2801824472","display_name":"Jewish General Hospital","ror":"https://ror.org/056jjra10","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I2801824472","https://openalex.org/I2801902503","https://openalex.org/I4210139015","https://openalex.org/I4405256057","https://openalex.org/I4405279980"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"N. A. Johnson","raw_affiliation_strings":["Jewish General Hospital, Montreal, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jewish General Hospital, Montreal, Canada","institution_ids":["https://openalex.org/I2801824472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110947408","display_name":"Abraham Avigdor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I16391192","display_name":"Tel Aviv University","ror":"https://ror.org/04mhzgx49","country_code":"IL","type":"education","lineage":["https://openalex.org/I16391192"]},{"id":"https://openalex.org/I2799810450","display_name":"Sheba Medical Center","ror":"https://ror.org/020rzx487","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2799810450"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"A. Avigdor","raw_affiliation_strings":["Sheba Medical Center, Ramat Gan, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sheba Medical Center, Ramat Gan, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel","institution_ids":["https://openalex.org/I16391192","https://openalex.org/I2799810450"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064132655","display_name":"Peter Borchmann","orcid":"https://orcid.org/0000-0003-3782-2158","observed_orcids":["https://orcid.org/0000-0003-3782-2158"]},"institutions":[{"id":"https://openalex.org/I4210153755","display_name":"University Hospital Cologne","ror":"https://ror.org/05mxhda18","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210153755"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"P. Borchmann","raw_affiliation_strings":["University Hospital of Cologne, Cologne, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital of Cologne, Cologne, Germany","institution_ids":["https://openalex.org/I4210153755"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091087189","display_name":"C. Andreadis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Andreadis","raw_affiliation_strings":["UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054086574","display_name":"Ali Bazargan","orcid":"https://orcid.org/0000-0001-6566-6215","observed_orcids":["https://orcid.org/0000-0001-6566-6215"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I4210087110","display_name":"St Vincent's Hospital Melbourne","ror":"https://ror.org/001kjn539","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210087110","https://openalex.org/I4210098850"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"A. Bazargan","raw_affiliation_strings":["University of Melbourne, Melbourne, and St Vincent\u2019s Hospital, Fitzroy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Melbourne, Melbourne, and St Vincent\u2019s Hospital, Fitzroy","institution_ids":["https://openalex.org/I165779595","https://openalex.org/I4210087110"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057423528","display_name":"Gareth Peter Gregory","orcid":"https://orcid.org/0000-0002-4170-0682","observed_orcids":["https://orcid.org/0000-0002-4170-0682"]},"institutions":[{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"G. Gregory","raw_affiliation_strings":["School of Clinical Sciences at Monash Health, Monash University, Melbourne"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Clinical Sciences at Monash Health, Monash University, Melbourne","institution_ids":["https://openalex.org/I4210121067","https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081797509","display_name":"Colm Keane","orcid":"https://orcid.org/0000-0002-9009-9934","observed_orcids":["https://orcid.org/0000-0002-9009-9934"]},"institutions":[{"id":"https://openalex.org/I2801814493","display_name":"Princess Alexandra Hospital","ror":"https://ror.org/04mqb0968","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I1302211766","https://openalex.org/I2801244131","https://openalex.org/I2801814493","https://openalex.org/I4210089726"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"C. Keane","raw_affiliation_strings":["Princess Alexandra Hospital, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Princess Alexandra Hospital, Brisbane, Australia","institution_ids":["https://openalex.org/I2801814493"]}]},{"author_position":"middle","author":{"id":null,"display_name":"T. Inna","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801301638","display_name":"Rambam Health Care Campus","ror":"https://ror.org/01fm87m50","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2801301638"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"T. Inna","raw_affiliation_strings":["Rambam Health Care Campus, Haifa, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rambam Health Care Campus, Haifa, Israel","institution_ids":["https://openalex.org/I2801301638"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060837326","display_name":"V. Vucinic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210125843","display_name":"University Hospital Leipzig","ror":"https://ror.org/028hv5492","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210125843"]},{"id":"https://openalex.org/I926574661","display_name":"Leipzig University","ror":"https://ror.org/03s7gtk40","country_code":"DE","type":"education","lineage":["https://openalex.org/I926574661"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"V. Vucinic","raw_affiliation_strings":["University of Leipzig Medical Center, Leipzig, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Leipzig Medical Center, Leipzig, Germany","institution_ids":["https://openalex.org/I4210125843","https://openalex.org/I926574661"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091882595","display_name":"Pier Luigi Zinzani","orcid":"https://orcid.org/0000-0002-2112-2651","observed_orcids":["https://orcid.org/0000-0002-2112-2651"]},"institutions":[{"id":"https://openalex.org/I4210117483","display_name":"Istituto di Ematologia di Bologna","ror":"https://ror.org/01mze9517","country_code":"IT","type":"facility","lineage":["https://openalex.org/I4210117483"]},{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"P. L. Zinzani","raw_affiliation_strings":["IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia \u201cSer\u00e0gnoli\u201d and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universit\u00e0 di Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I4210117483","https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021303244","display_name":"H. Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Zhang","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086252694","display_name":"Pallavi M. Pillai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Pillai","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038208984","display_name":"Patricia Maria Marinello","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Marinello","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5107833759","display_name":"John M. Timmerman","orcid":"https://orcid.org/0000-0003-4104-8943","observed_orcids":["https://orcid.org/0000-0003-4104-8943"]},"institutions":[{"id":"https://openalex.org/I2801272649","display_name":"Ronald Reagan UCLA Medical Center","ror":"https://ror.org/04k3jt835","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801272649"]},{"id":"https://openalex.org/I2801403999","display_name":"UCLA Medical Center","ror":"https://ror.org/04vq5kb54","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801403999"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Timmerman","raw_affiliation_strings":["UCLA Medical Center, Los Angeles, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Medical Center, Los Angeles, United States of America","institution_ids":["https://openalex.org/I2801272649","https://openalex.org/I2801403999"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":22,"corresponding_author_ids":["https://openalex.org/A5030788778"],"corresponding_institution_ids":["https://openalex.org/I1301076528","https://openalex.org/I4210110459"],"apc_list":{"value":2480,"currency":"USD","value_usd":2480},"apc_paid":{"value":2480,"currency":"USD","value_usd":2480},"fwci":0.3385,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.54085387,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":96},"biblio":{"volume":"6","issue":null,"first_page":"977","last_page":"978"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.035999998450279236,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9869999885559082},{"id":"https://openalex.org/keywords/lag-3","display_name":"LAG-3","score":0.8320000171661377},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.7289999723434448},{"id":"https://openalex.org/keywords/dual-immune-checkpoint-blockade","display_name":"dual immune checkpoint blockade","score":0.859000027179718},{"id":"https://openalex.org/keywords/anti-pd-1-resistance","display_name":"anti-PD-1 resistance","score":0.7319999933242798},{"id":"https://openalex.org/keywords/autoimmune-hepatitis","display_name":"autoimmune hepatitis","score":0.6970000267028809},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7649999856948853},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8619999885559082},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7480000257492065},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6880000233650208},{"id":"https://openalex.org/keywords/treatment-efficacy-and-safety","display_name":"treatment efficacy and safety","score":0.5379999876022339},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.6380000114440918},{"id":"https://openalex.org/keywords/dose-finding","display_name":"dose-finding","score":0.3330000042915344},{"id":"https://openalex.org/keywords/autoimmune-adverse-events","display_name":"autoimmune adverse events","score":0.3019999861717224}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8444733619689941},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7816890478134155},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6456652879714966},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6376186609268188},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5459910035133362},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5003139972686768},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4961436688899994},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.48337048292160034},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.48182740807533264},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.42935341596603394},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35651206970214844},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.33128198981285095},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.28507038950920105},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2817856967449188},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.21284523606300354},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.18248996138572693},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1097/01.hs9.0000847216.85071.f3","doi":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9430340","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9430340","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hemasphere","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:2166d16878014796a031baf1d6833174","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/2166d16878014796a031baf1d6833174","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"HemaSphere, Vol 6, Pp 977-978 (2022)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1097/01.hs9.0000847216.85071.f3","doi":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000847216.85071.f3","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4283325297","https://openalex.org/W4385702448","https://openalex.org/W4379979648","https://openalex.org/W4389220730","https://openalex.org/W4281670144","https://openalex.org/W4310103279","https://openalex.org/W4385705955","https://openalex.org/W4389246769","https://openalex.org/W4385698344","https://openalex.org/W4303983476"],"abstract_inverted_index":{"Background:":[0],"PD-1":[1,36,70],"inhibitors":[2],"are":[3],"a":[4,63,95,110,185,371,423,540,568],"standard":[5],"of":[6,35,60,139,145,178,240,342,374,399,412,418,519],"care":[7],"for":[8,25,128,203,378,432],"relapsed":[9,123],"or":[10,125,170,210,218,362,366,509],"refractory":[11,87],"(R/R)":[12],"classical":[13],"Hodgkin":[14],"lymphoma":[15],"(cHL),":[16],"but":[17],"optimal":[18],"therapy":[19,141,413],"is":[20],"yet":[21],"to":[22,88,101,205,287,356,446,524],"be":[23],"defined":[24,307],"patients":[26,74,83,116,151,194,268,298,321,351,379,420,433,451,488,515,520,551],"whose":[27,555],"disease":[28,213,360,556],"progresses":[29],"after":[30,124,136,559],"anti\u2013PD-1":[31,89,140,560],"treatment.":[32],"Dual":[33],"blockade":[34],"and":[37,58,134,165,229,246,334,497,501,503,517,544],"lymphocyte-activation":[38],"gene":[39],"3":[40,162,508],"(LAG-3)":[41],"has":[42],"demonstrated":[43],"antitumor":[44,546],"activity":[45,547],"in":[46,73,117,273,294,427,452,486,513,548,570],"preclinical":[47],"models.":[48],"Aims:":[49],"This":[50,92],"multicohort":[51],"phase":[52,98,104,112],"1/2":[53],"study":[54,93,415],"(NCT03598608)":[55],"evaluated":[56],"safety":[57,96,542],"efficacy":[59],"favezelimab":[61,166,198,278,381,436],"(MK-4280),":[62],"humanized":[64],"IgG4":[65],"LAG-3":[66],"inhibitor,":[67],"plus":[68],"the":[69,200,265,277,283,295,300,455,564],"inhibitor":[71],"pembrolizumab":[72,158,196,313,535],"with":[75,84,552],"R/R":[76,85,121,553],"hematologic":[77],"malignancies.":[78],"Cohort":[79],"2":[80,105,119,206,392],"focused":[81],"on":[82,176],"cHL":[86,554],"therapy.":[90,343],"Methods:":[91],"included":[94,272],"lead-in":[97],"(part":[99,113],"1)":[100],"determine":[102],"recommended":[103],"dose":[106,284],"(RP2D)":[107],"followed":[108],"by":[109],"dose-expansion":[111],"2).":[114],"Eligible":[115],"cohort":[118,318,453],"had":[120,330,336,352,403,422,557],"cHL,":[122],"were":[126,250,292,322,493],"ineligible":[127],"autologous":[129],"stem":[130],"cell":[131],"transplantation":[132],"(ASCT),":[133],"progressed":[135,558],"\u22652":[137],"doses":[138],"(within":[142],"12":[143],"weeks":[144,163],"last":[146],"dose).":[147],"In":[148,191,317],"part":[149,192,274],"1,":[150,348],"from":[152,220,269,425],"all":[153,270,450],"cohorts":[154,271],"received":[155,195,435],"intravenous":[156],"(IV)":[157],"200":[159,168,279,314,536],"mg":[160,169,172,280,302,310,315,383,438,533,537],"every":[161],"(Q3W)":[164],"IV":[167],"800":[171,288,301,309,382,437,532],"Q3W.":[173,316],"Dose-finding":[174],"based":[175],"occurrence":[177],"dose-limiting":[179],"toxicities":[180],"(DLT)":[181],"was":[182,225,234,262,285,306,326,385,439,458,467,471,480],"determined":[183],"using":[184],"modified":[186],"toxicity":[187],"probability":[188],"interval":[189],"design.":[190],"2,":[193,319,454],"+":[197,312,534],"at":[199,276,299,337,414],"established":[201],"RP2D":[202,305],"up":[204],"years":[207],"(35":[208],"cycles),":[209],"until":[211],"documented":[212],"progression,":[214],"adverse":[215,357],"events":[216,358],"(AEs),":[217],"withdrawal":[219],"study.":[221],"Primary":[222],"end":[223,232,252],"point":[224,233],"safety,":[226],"including":[227],"DLTs":[228,291],"AEs.":[230],"Secondary":[231],"objective":[235],"response":[236,241,569],"rate":[237,466,479],"(ORR).":[238],"Duration":[239],"(DOR),":[242],"progression-free":[243],"survival":[244,248],"(PFS),":[245],"overall":[247],"(OS)":[249],"exploratory":[251],"points.":[253],"Results:":[254],"Only":[255],"1":[256,275],"DLT":[257],"(autoimmune":[258],"hepatitis":[259],"[grade":[260],"4])":[261],"observed":[263,293],"among":[264],"first":[266],"6":[267,514],"dose;":[281],"thus,":[282],"escalated":[286],"mg.":[289],"No":[290,526],"15":[296],"additional":[297],"dose.":[303],"Favezelimab":[304,531],"as":[308,407],"Q3W":[311,538],"33":[320],"enrolled;":[323],"median":[324,372,456],"age":[325],"37":[327],"years,":[328],"64%":[329],"ECOG":[331],"PS":[332],"0,":[333],"94%":[335],"least":[338],"4":[339,510],"prior":[340],"lines":[341],"At":[344],"database":[345],"cutoff":[346],"(Nov":[347],"2021),":[349],"20":[350],"discontinued":[353,521],"treatment":[354,522],"due":[355,523],"(n=7);":[359],"progression":[361,364],"clinical":[363],"(n=11);":[365],"withdrawal/physician":[367],"decision":[368],"(n=2).":[369],"After":[370],"follow-up":[373],"16.5":[375],"months,":[376],"ORR":[377],"receiving":[380],"(n=29)":[384],"31%":[386],"(95%":[387,461,474],"CI,":[388,444,462,475],"15-51;":[389],"complete":[390],"response,":[391,395],"[7%];":[393],"partial":[394],"7":[396],"[24%]).":[397],"19":[398],"29":[400,419],"responders":[401],"(66%)":[402],"an":[404],"anti\u2013PD-1\u2013based":[405],"regimen":[406],"their":[408],"most":[409,490],"recent":[410],"line":[411],"entry.":[416],"23":[417],"(79%)":[421],"reduction":[424],"baseline":[426],"target":[428],"lesions.":[429],"Median":[430,469],"DOR":[431],"who":[434],"not":[440],"reached":[441],"([NR];":[442],"95%":[443],"0+":[445],"14+":[447],"months).":[448],"For":[449],"PFS":[457,465],"9":[459],"months":[460,473],"5-15);":[463],"12-month":[464,477],"39%.":[468],"OS":[470,478],"26":[472],"26-NR);":[476],"91%.":[481],"Treatment-related":[482],"AEs":[483],"(TRAE)":[484],"occurred":[485,512],"28":[487],"(85%);":[489],"common":[491],"(>10%)":[492],"hypothyroidism":[494],"(18%),":[495],"nausea":[496],"fatigue":[498],"(15%":[499],"each),":[500],"arthralgia":[502],"diarrhea":[504],"(12%":[505],"each).":[506],"Grade":[507],"TRAEs":[511],"(18%)":[516],"18%":[518],"TRAEs.":[525],"treatment-related":[527],"deaths":[528],"occurred.":[529],"Summary/Conclusion:":[530],"showed":[539],"tolerable":[541],"profile":[543],"effective":[545],"heavily":[549],"pretreated":[550],"therapy,":[561],"suggesting":[562],"that":[563],"combination":[565],"may":[566],"reinduce":[567],"these":[571],"patients.":[572]},"counts_by_year":[{"year":2024,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-06-24T00:00:00"}